- Home
- CNVS vs MREO Comparison
CNVS vs MREO Comparison
Compare CNVS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNVS | MREO |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 52.5M |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNVS | MREO |
|---|---|---|
| Price | $2.47 | $0.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $9.00 | $1.50 |
| AVG Volume (30 Days) | 145.8K | ★ 1.5M |
| Earning Date | 02-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,181,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $84.42 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $0.20 |
| 52 Week High | $7.39 | $2.94 |
Technical Indicators
Market Signals| Indicator | CNVS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 36.78 |
| Support Level | $2.31 | $0.20 |
| Resistance Level | $2.56 | $0.36 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 52.81 | 26.73 |
Price Performance
Historical ComparisonAbout CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).